Cary, North Carolina Clinical Trials

A listing of Cary, North Carolina clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
featured
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.

hypertensive medication
angiography
hypertension
antihypertensive drugs
antihypertensive therapy
WakeMed Raleigh
 (9.9 away) Contact site
  • 877 views
  • 01 Aug, 2021
  • +82 other locations
featured
C2541013 MIRNA NASH  

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

M3 Wake Research Associates
 (7.7 away)
  • 275 views
  • 30 Jul, 2021
  • +64 other locations
Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria

The purpose of this study is to determine the efficacy, durability and long-term safety of reloxaliase in patients with enteric hyperoxaluria.

Associated Urologists of North Carolina
 (8.0 away) Contact site
  • 7 views
  • 04 Aug, 2021
  • +83 other locations
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Galderma Investigational Site
 (8.0 away) Contact site
  • 21 views
  • 04 Aug, 2021
  • +470 other locations
Efficacy Safety and Tolerability of Atogepant for the Prevention of Chronic Migraine

This study will evaluate the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study includes a 12-week treatment period.

migraine
headache
Raleigh Neurology Associates, P.A
 (5.7 away) Contact site
  • 576 views
  • 24 Jul, 2021
  • +178 other locations
Fixed-Dose Trial in Early Parkinson's Disease (TemPo-1)

The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early Parkinson's Disease.

hallucinations
essential tremor
early parkinson's
dopa
dopamine agonists
Raleigh Neurology Associates
 (5.7 away) Contact site
  • 0 views
  • 31 Jul, 2021
  • +76 other locations
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).

aubagio
teriflunomide
evobrutinib
Research Site 730
 (5.7 away) Contact site
  • 0 views
  • 31 Jul, 2021
  • +258 other locations
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine

Raleigh Neurology Associates, P.A
 (5.7 away) Contact site
  • 0 views
  • 22 Jul, 2021
  • +177 other locations
The Merit WRAPSODY AV Access Efficacy Study (WAVE)

The purpose of the study is to demonstrate the safety and efficacy of the Merit WRAPSODY Endovascular Stent Graft for treatment of stenosis or occlusion within the dialysis access outflow circuit

NC Heart and Vascular Research
 (7.9 away) Contact site
  • 0 views
  • 24 Jul, 2021
  • +41 other locations
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer the CompassHER2 RD Trial

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted …

Rex Cancer Center
 (5.7 away) Contact site
  • 0 views
  • 26 Jul, 2021
  • +762 other locations